183 related articles for article (PubMed ID: 2502417)
41. Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.
Crook D; Bruce R; Worthington M; Mulcahy D; Patterson D; Wynn V
Cardiovasc Drugs Ther; 1992 Dec; 6(6):633-9. PubMed ID: 1292582
[TBL] [Abstract][Full Text] [Related]
42. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators.
Simons LA
Clin Cardiol; 1993 Apr; 16(4):317-22. PubMed ID: 8458112
[TBL] [Abstract][Full Text] [Related]
43. Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Neuman MP; Neuman HR; Neuman J
Atherosclerosis; 1991 Dec; 91 Suppl():S11-9. PubMed ID: 1789812
[TBL] [Abstract][Full Text] [Related]
44. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
Eriksson M; Hådell K; Holme I; Walldius G; Kjellström T
J Intern Med; 1998 May; 243(5):373-80. PubMed ID: 9651560
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and tolerability of medium-term treatment with simvastatin in primary hypercholesterolaemia.
Marnini P; Colombo F; Cattaneo R; Geroli L; Venco A
Int J Clin Pharmacol Res; 1992; 12(2):65-70. PubMed ID: 1428300
[TBL] [Abstract][Full Text] [Related]
46. Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia.
Uusitupa M; Ebeling T; Happonen P; Voutilainen E; Turtola H; Parviainen M; Pyörälä K
J Cardiovasc Pharmacol; 1991 Oct; 18(4):496-503. PubMed ID: 1724525
[TBL] [Abstract][Full Text] [Related]
47. [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
Martens LL; Rutten FF; Kuijpens JL; Winter J
Ned Tijdschr Geneeskd; 1991 Apr; 135(15):655-9. PubMed ID: 1903849
[TBL] [Abstract][Full Text] [Related]
48. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group.
Itoh T; Matsumoto M; Hougaku H; Handa N; Tsubakihara Y; Yamada Y; Imaizumi M; Hoshi M; Shimazu Y; Hori M; Kawamori R; Ueda N; Fusamoto H; Kamada T
Clin Ther; 1997; 19(3):487-97. PubMed ID: 9220213
[TBL] [Abstract][Full Text] [Related]
49. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
Lintott CJ; Scott RS; Sharpe DN; Nye ER; Charleson H; French JK; White HD; Reuben S; Maling TJ; Lewis GR
Med J Aust; 1991 Oct; 155(7):433-6. PubMed ID: 1921811
[TBL] [Abstract][Full Text] [Related]
50. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
[TBL] [Abstract][Full Text] [Related]
51. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia.
Vessby B; Kostner G; Lithell H; Thomis J
Atherosclerosis; 1982 Jul; 44(1):61-71. PubMed ID: 6214264
[TBL] [Abstract][Full Text] [Related]
52. Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia.
Weisweiler P
Eur J Clin Pharmacol; 1988; 35(6):579-83. PubMed ID: 3234467
[TBL] [Abstract][Full Text] [Related]
53. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
Watts GF; Cummings MH; Umpleby M; Quiney JR; Naoumova R; Thompson GR; Sönksen PH
Eur J Clin Invest; 1995 Aug; 25(8):559-67. PubMed ID: 7589011
[TBL] [Abstract][Full Text] [Related]
54. [The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].
Fricker J; Douste-Blazy P; Drouin P; De Gennes JL; Dachet C; Keller U
Presse Med; 1990 Dec; 19(42):1927-30. PubMed ID: 2147752
[TBL] [Abstract][Full Text] [Related]
55. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation.
Barbir M; Rose M; Kushwaha S; Akl S; Mitchell A; Yacoub M
Int J Cardiol; 1991 Nov; 33(2):241-6. PubMed ID: 1743784
[TBL] [Abstract][Full Text] [Related]
56. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Dart A; Jerums G; Nicholson G; d'Emden M; Hamilton-Craig I; Tallis G; Best J; West M; Sullivan D; Bracs P; Black D
Am J Cardiol; 1997 Jul; 80(1):39-44. PubMed ID: 9205017
[TBL] [Abstract][Full Text] [Related]
57. Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia.
Steyn K; Weich HF; Bonnici F; Kotze TJ; Stander I; Vermaak WJ; Lourens W; van Lathem J; Omar MA; Fourie J
S Afr Med J; 1992 Dec; 82(6):402-6. PubMed ID: 1465688
[TBL] [Abstract][Full Text] [Related]
58. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Bach LA; Cooper ME; O'Brien RC; Jerums G
J Am Geriatr Soc; 1990 Jan; 38(1):10-4. PubMed ID: 2404052
[TBL] [Abstract][Full Text] [Related]
59. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system.
Sandset PM; Lund H; Norseth J; Abildgaard U; Ose L
Arterioscler Thromb; 1991; 11(1):138-45. PubMed ID: 1987991
[TBL] [Abstract][Full Text] [Related]
60. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects.
Miserez AR; Rossi FA; Keller U
Eur J Clin Pharmacol; 1994; 46(2):107-14. PubMed ID: 8039527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
